Globus Medical, Inc. (NYSE:GMED) Receives $106.36 Average PT from Analysts

Shares of Globus Medical, Inc. (NYSE:GMED) have earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $106.3636.

A number of research analysts recently commented on the company. Barclays raised their price target on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Wells Fargo & Company decreased their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Truist Financial set a $115.00 price target on Globus Medical in a research report on Wednesday, February 25th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th.

Globus Medical Price Performance

GMED stock opened at $78.28 on Wednesday. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The stock has a market capitalization of $10.63 billion, a price-to-earnings ratio of 18.20, a PEG ratio of 1.65 and a beta of 0.95. The business’s fifty day moving average price is $86.88 and its two-hundred day moving average price is $88.39.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same quarter last year, the business earned $0.68 earnings per share. Globus Medical’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts expect that Globus Medical will post 4.74 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GMED. Advisory Services Network LLC acquired a new stake in Globus Medical in the third quarter valued at about $26,000. EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares in the last quarter. SBI Securities Co. Ltd. boosted its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares in the last quarter. Parallel Advisors LLC boosted its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Globus Medical in the third quarter valued at about $36,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.